Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing rapid-acting, self-administered therapies for episodic cardiovascular conditions. Headquartered in Montréal, Canada, with U.S. operations in Charlotte, North Carolina, the company is publicly listed on Nasdaq (MIST).
Milestone’s lead program is etripamil, a short-acting calcium channel blocker formulated for intranasal delivery and being evaluated for the on-demand treatment of paroxysmal supraventricular tachycardia (PSVT) and other arrhythmias. The company’s research centers on small-molecule chemistry and drug–device combinations intended to help patients manage sudden cardiovascular events outside of acute care settings.
None yet. When a new project in the record names Milestone Pharmaceuticals as owner, partner or investor, it shows here.
CARDAMYST, a self-administered nasal spray for PSVT, offers reliable, easy-to-use treatment with Aptar's protective dual-container system, enhancing drug delivery solutions.
